Posted by Michael Wonder on 06 Feb 2023
Sage Therapeutics and Biogen announce FDA accepts filing of new drug application and grants priority review of zuranolone in the treatment of major depressive disorder and post-partum depression
6 February 2023 - Zuranolone is being evaluated as a potential 14 day, rapid acting, once daily, oral medication to treat major depressive disorder and post-partum depression.
The application has been granted priority review and the FDA has assigned a PDUFA action date of 5 August 2023.
